Patents by Inventor Howard E. Gendelman

Howard E. Gendelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12156912
    Abstract: Methods and compositions for treating central nervous system diseases and disorders are disclosed. In a particular embodiment, compositions comprising a nitrated alpha synuclein peptide are provided. The composition may further comprise an adjuvant that stimulates regulatory T cells and/or at least one pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: December 3, 2024
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard E. Gendelman, R. Lee Mosley
  • Publication number: 20240165266
    Abstract: Disclosed herein are methods and compositions for lipid nanoparticles encapsulating a nucleic acid encoding for a CRISPR nucleic acid complementary to a HIV-1 gene. Also disclosed are lipid nanoparticle compositions, nucleotides, cells, and methods associated with the compositions.
    Type: Application
    Filed: March 17, 2022
    Publication date: May 23, 2024
    Inventors: Howard E. Gendelman, Jonathan Herskovitz, Mahmudul Hasan, Bhavesh Kevadiya, Milankumar Patel
  • Publication number: 20240139310
    Abstract: The present invention provides porous microparticles, particularly layer-by-layer microparticles, and methods of use thereof.
    Type: Application
    Filed: March 9, 2022
    Publication date: May 2, 2024
    Inventors: Howard E. GENDELMAN, Bhavesh Kevadiya, Farah Shahjin, Milankumar Patel
  • Publication number: 20240100171
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: October 27, 2022
    Publication date: March 28, 2024
    Inventors: Howard E. Gendelman, Benson Edagwa
  • Patent number: 11839623
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: December 12, 2023
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Howard E. Gendelman, Benson Edagwa
  • Patent number: 11806385
    Abstract: The present invention provides novel biomarkers for regulatory T cells (Treg) function and Parkinson's disease.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: November 7, 2023
    Assignees: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Howard E. Gendelman, R. Lee Mosley, Gary Siuzdak, Erica Forsberg
  • Patent number: 11458136
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: October 4, 2022
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard E. Gendelman, Benson Edagwa
  • Publication number: 20220211714
    Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
    Type: Application
    Filed: March 16, 2022
    Publication date: July 7, 2022
    Inventors: Howard E. Gendelman, Xin-Ming Liu, Benson Edagwa
  • Publication number: 20220194990
    Abstract: The present invention provides virus-like particles and methods of manufacture and use thereof. In accordance with the instant invention, virus-like particles (VLPs), particularly human immunodeficiency virus (HIV) VLPs, are provided. The HIV VLPs comprise at least one HIV structural protein and the HIV envelope protein, but lacks the HIV genome and lacks functional reverse transcriptase and integrase.
    Type: Application
    Filed: January 31, 2020
    Publication date: June 23, 2022
    Inventors: Howard E. Gendelman, Jonathan Herskovitz, Mahmudul Hasan, Bhavesh Kevadiya
  • Patent number: 11311545
    Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: April 26, 2022
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard E. Gendelman, Xin-Ming Liu, Benson Edagwa
  • Publication number: 20220091111
    Abstract: Methods and compositions for detecting and diagnosing Parkinson's disease are disclosed.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Inventors: Howard E. Gendelman, R. Lee Mosley, Jessica A. Saunders
  • Patent number: 11209426
    Abstract: Methods and compositions for detecting and diagnosing Parkinson's disease are disclosed.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: December 28, 2021
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Howard E. Gendelman, R. Lee Mosley, Jessica A. Saunders
  • Patent number: 11117904
    Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: September 14, 2021
    Assignees: ViiV Healthcare Company, Board of Regents of University of Nebraska
    Inventors: Benson J. Edagwa, Howard E. Gendelman, Brian Alvin Johns
  • Publication number: 20210230186
    Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
    Type: Application
    Filed: June 22, 2017
    Publication date: July 29, 2021
    Inventors: Benson J. EDAGWA, Howard E. GENDELMAN, Brian Alvin JOHNS
  • Publication number: 20210113558
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: April 9, 2019
    Publication date: April 22, 2021
    Applicant: Board of Regents of the University of Nebraska
    Inventors: Howard E. GENDELMAN, Benson EDAGWA
  • Publication number: 20210060138
    Abstract: Methods of eliminating a retrovirus from a subject utilize nanoformulated anti-retroviral compounds and gene editing agents. Compositions comprise at least one anti-retroviral compounds, at least one gene-editing agent, or combinations thereof.
    Type: Application
    Filed: March 6, 2020
    Publication date: March 4, 2021
    Applicants: Temple University - of the Commonwealth System of Higher Education, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Kamel Khalili, Howard E. Gendelman, Benson Edagwa
  • Publication number: 20200390796
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: January 14, 2019
    Publication date: December 17, 2020
    Inventors: Howard E. Gendelman, Benson Edagwa
  • Publication number: 20200140865
    Abstract: Methods of eliminating a retrovirus from a subject utilize nanoformulated anti-retroviral compounds and gene editing agents. Compositions comprise at least one anti-retroviral compounds, at least one gene-editing agent, or combinations thereof.
    Type: Application
    Filed: April 9, 2018
    Publication date: May 7, 2020
    Inventors: Kamel Khalili, Howard E. Gendelman, Edgawa Benson
  • Patent number: 10485800
    Abstract: Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.
    Type: Grant
    Filed: November 30, 2013
    Date of Patent: November 26, 2019
    Assignees: The University of Rochester, Board of Regents of the University of Nebraska
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Howard E. Gendelman
  • Publication number: 20190117735
    Abstract: The present invention provides novel biomarkers for regulatory T cells (Treg) function and Parkinson's disease.
    Type: Application
    Filed: April 24, 2017
    Publication date: April 25, 2019
    Inventors: Howard E. Gendelman, R. Lee Mosley, Gary Suizdak, Erica Forsberg